Brief: Aditxt Subsidiary Pearsanta Receives Irb Approval To Initiate Clinical Study Of Blood-Based Diagnostic For Endometriosis With Patient Enrollment Planned To Begin In May 2025
16/04/2025 14:08
April 16 (Reuters) - Aditxt Inc ADTX.O: ADITXT SUBSIDIARY PEARSANTA RECEIVES IRB APPROVAL TO INITIATE CLINICAL STUDY OF BLOOD-BASED DIAGNOSTIC FOR ENDOMETRIOSIS WITH PATIENT ENROLLMENT PLANNED TO BEGIN IN MAY 2025 Source text: ID:nBwLDSgNa Further company coverage: ADTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aditxt
See all newsBrief: Ignite Proteomics Announces 10,000-Patient Oncology Registry For Therapy Selection
Brief: Aditxt Appoints Jeffrey M. Busch As Interim CEO; Founder And Former CEO Of $1B NYSE Enterprise Which Delivered ~8.5% Dividends To Shareholders
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM